You are here

  • Home
  • Online First
  • Quality of skeletal muscles during allogeneic stem-cell transplantation: a pilot study

Article Text

Article menu
Download PDFPDF
Short report
Quality of skeletal muscles during allogeneic stem-cell transplantation: a pilot study
  1. Yusaku Maeda1,
  2. Shoichiro Takao2,
  3. Shiori Morita3,
  4. Shin Kondo4,
  5. Michiko Yamashita5,
  6. Ryohei Sumitani1,
  7. Masahiro Oura1,
  8. Kimiko Sogabe1,
  9. Mamiko Takahashi6,
  10. Shiro Fujii1,
  11. Takeshi Harada1,
  12. Hirokazu Miki7,
  13. Masahiro Abe6 and
  14. Shingen Nakamura8
  1. 1Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
  2. 2Department of Diagnostic Radiology, Tokushima University Graduate School of Health Sciences, Tokushima, Japan
  3. 3Department of Diagnostic Imaging, Shinko Hospital, Kobe, Hyogo, Japan
  4. 4Division of Rehabilitation, Tokushima University Hospital, Tokushima, Japan
  5. 5Department of Analytical Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
  6. 6Department of Hematology, Kawashima Hospital, Tokushima, Japan
  7. 7Division of Transfusion Medicin and Cell Therapy, Tokushima University Hospital, Tokushima, Japan
  8. 8Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
  1. Correspondence to Dr Shingen Nakamura; shingen{at}tokushima-u.ac.jp

Abstract

Objectives This study investigated the muscle fat fraction (FF) and muscle-related parameters before and after allogeneic hematopoietic stem cell transplantation (HSCT).

Methods Fat and water signals were derived from the in-phase and out-of-phase MR signal intensities of the pelvis and thigh using the two-point Dixon technique. They were analysed using Synapse Vincent, and muscle quality was evaluated using the FF. The muscle mass was assessed by measuring the thigh and gluteal muscle areas using a manual trace on the MR image. The association between the muscle FF and clinical data was retrospectively determined.

Results This study included 11 patients (6 males). Their mean age was 42.7 years, and eight had leukaemia. Eight were assessed at a mean of 65.4 days post-HSCT. The hip and thigh skeletal muscle FFs were not significantly different during HSCT. The grip and lower limb muscle strengths decreased significantly after HSCT. Patients with low FFs before transplantation tended to lose muscle strength, and the increase in FF and decrease of muscle strength were correlated.

Conclusions Muscle strength and quantity decrease during the early phase after HSCT, especially in patients with low FF muscles. Therefore, interventions based on muscle quality and quantity are essential.

  • Leukaemia
  • Palliative Care

https://doi.org/10.1136/spcare-2024-005070

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors Conceptualisation: ST, SK and SN. Data acquisition and processing: SM, YM, ST, MY, SN and SK. Clinical work for the patients: YM, SN, RS, MO, KS, MT, TH, SF, MA and HM. Writing—original draft preparation: YM and SN. Writing—revised draft and editing: ST, MY and MA. Manuscript supervision: MY. Project administration: SN, ST and MY. All authors have read and agreed to the published version of the manuscript. SN is the guarantor.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.